Literature DB >> 1372377

Influence of preoperative treatment and surgical operation on immune function of patients with esophageal carcinoma.

S Tsutsui1, M Morita, H Kuwano, H Matsuda, M Mori, S Okamura, K Sugimachi.   

Abstract

Multiple immunological parameters, including total lymphocyte count, lymphocyte subpopulations (CD2+, CD19+, CD3+, CD4+ and CD8+), phytohemagglutinin (PHA) response, and natural killer (NK) activity, were measured in 66 patients with previously untreated esophageal carcinoma. The influence of preoperative treatment and/or surgical operation on the immune function were evaluated in 40 patients. The PHA response and NK activity of the patients with esophageal carcinoma were 229 +/- 103 S.I.% and 18.5 +/- 11.9% lysis, respectively, and were significantly depressed as compared with the control. The CD4+/CD8+ ratio, PHA response, and NK activity in stage IV were also significantly depressed compared to that in stages I-III. Preoperative treatment induced significant reductions in the total lymphocyte count (1,994 +/- 644 to 670 +/- 274/mm3), PHA response (219 +/- 77 to 159 +/- 59 S.I.%), and NK activity (19.7 +/- 13.2 to 11.1 +/- 10.3% lysis) as well as a significant gradual decrease in the CD4+/CD8+ ratio (2.09 +/- 1.42 to 0.69 +/- 0.48), while the surgical operation significantly influenced only the total lymphocyte count. This study demonstrates that preoperative treatment induces a more pronounced influence on the immune function than surgical operation alone, in patients with esophageal carcinoma in which the immune function is disturbed prior to these treatments.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1372377     DOI: 10.1002/jso.2930490310

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  8 in total

1.  Impact of perioperative peripheral blood values on postoperative complications after esophageal surgery.

Authors:  Hiroshi Saeki; Takanobu Masuda; Satoko Okada; Koji Ando; Masahiko Sugiyama; Keiji Yoshinaga; Kazuya Endo; Noriaki Sadanaga; Yasunori Emi; Yoshihiro Kakeji; Masaru Morita; Natsumi Yamashita; Yoshihiko Maehara
Journal:  Surg Today       Date:  2010-06-26       Impact factor: 2.549

Review 2.  Neoadjuvant therapy for advanced esophageal cancer: the impact on surgical management.

Authors:  Masahiko Ikebe; Masaru Morita; Manabu Yamamoto; Yasushi Toh
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-05-10

3.  Decreased NKG2D expression on NK cells correlates with impaired NK cell function in patients with gastric cancer.

Authors:  Hiroaki Saito; Tomohiro Osaki; Masahide Ikeguchi
Journal:  Gastric Cancer       Date:  2011-05-31       Impact factor: 7.370

4.  Increased apoptosis and elevated Fas expression in circulating natural killer cells in gastric cancer patients.

Authors:  Hiroaki Saito; Seigo Takaya; Tomohiro Osaki; Masahide Ikeguchi
Journal:  Gastric Cancer       Date:  2012-11-22       Impact factor: 7.370

5.  Endoscopically defined treatment strategies in patients with locally advanced esophageal cancer.

Authors:  J A Greager; P E Donahue; K Reichard; V Kucich; M Lubienski; W Barker; H M Reyes
Journal:  Surg Endosc       Date:  1994-05       Impact factor: 4.584

6.  Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection.

Authors:  A G Heriot; J B Marriott; S Cookson; D Kumar; A G Dalgleish
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

7.  Comparative analysis of CD4+ and CD8+ T cells in tumor tissues, lymph nodes and the peripheral blood from patients with breast cancer.

Authors:  Farhad Riazi Rad; Soheila Ajdary; Ramesh Omranipour; Mohammad Hossein Alimohammadian; Zahir M Hassan
Journal:  Iran Biomed J       Date:  2015

8.  Correlation Between Natural Killer Cell Activity and Systemic Inflammatory Markers for Heterogeneous Cancer Patients Treated With Wheel Balance Cancer Therapy.

Authors:  Hwi-Joong Kang; Kyeore Bae; Jee-Hye Kim; Chong-Kwan Cho; Hwa-Seung Yoo
Journal:  Integr Cancer Ther       Date:  2017-07-17       Impact factor: 3.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.